Discounted Cash Flow
Beone Medicines Ltd. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.1m | $-119.2m | $-113.0m | -11141.8% | $-0.30 |
| 2017 | $238.4m (22179.2%) | $-93.1m (21.9%) | $-33.6m (70.2%) | -39.1% (99.6%) | $-2.23 (-643.3%) |
| 2018 | $198.2m (-16.8%) | $-673.8m (-623.7%) | $-618.0m (-1738.1%) | -339.9% (-770.3%) | $-12.15 (-444.8%) |
| 2019 | $428.2m (116.0%) | $-948.6m (-40.8%) | $-839.9m (-35.9%) | -221.5% (34.8%) | $-15.80 (-30.0%) |
| 2020 | $308.9m (-27.9%) | $-1.6b (-68.3%) | $-1.4b (-66.8%) | -517.0% (-133.4%) | $-19.13 (-21.1%) |
| 2021 | $1.2b (280.8%) | $-1.4b (11.5%) | $-1.6b (-11.5%) | -120.2% (76.8%) | $-1.17 (93.9%) |
| 2022 | $1.4b (20.4%) | $-2.0b (-41.8%) | $-1.8b (-16.7%) | -141.5% (-17.8%) | $-1.49 (-27.4%) |
| 2023 | $2.5b (73.7%) | $-881.7m (56.0%) | $-1.7b (5.6%) | -35.9% (74.7%) | $-0.65 (56.4%) |
| 2024 | $3.8b (55.0%) | $-644.8m (26.9%) | $-633.3m (63.2%) | -16.9% (52.8%) | $-0.47 (27.7%) |
| 2025 | $5.3b (40.2%) | $286.9m (144.5%) | $941.7m (248.7%) | 5.4% (131.7%) | $0.20 (142.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.